We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Collaboration to Develop Neurodegenerative Tests

By HospiMedica staff writers
Posted on 10 Apr 2002
A licensing agreement and a research collaboration for the development of in vitro diagnostic tests for neurodegenerative diseases related to the presence of abnormal prion proteins in humans and animals has been announced by Abbott Laboratories (Abbott Park, IL, USA) and the University of Zurich (Switzerland).

The abnormal proteins are associated with bovine spongiform encephalopathy (BSE), or mad cow disease, in cattle. More...
The human equivalent is new variant Creutzfeldt Jakob disease (nvCJD). Under the licensing agreement, Abbott obtains nonexclusive rights to the university's technologies for the specific binding of disease-associated prion proteins for use in the field of human and veterinary diagnostics. Abbott also obtains exclusive rights to any improvements made as a result of the collaboration. Under an agreement with Enfer Scientific Ltd., Abbott currently markets a post-mortem diagnostic test used outside the United States for detecting BSE in cattle.

"The University of Zurich's technologies and extensive research expertise in prions represent a significant strength in furthering our ability to develop both human and animal diagnostic tests for the early detection of infectious prions,” said James J. Koziarz, Ph.D., vice president, diagnostic products research and development, Abbott Laboratories.




Related Links:
Abbott
Univ. of Zurich

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.